Loading…
IMMUTEP Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -93.8% over 5Y.
today you would have $68.09▼ -93.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $0.26 | $2.17 | $2.40 | $1.75 | |
| P/S | — | 26.7x | — | — | 9121.4x |
| P/B | 16.6x | 6.3x | 16.6x | 21.1x | 16.5x |
| EPS | -$0.54 | -$0.36 | -$0.45 | — | |
| Profit margin | — | -544.79% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HRTXHeron Therapeutics Inc | $0.29 | — | 9.4x | — | — | $55.25M |
| SRTSSensus Healthcare, Inc. | $3.52 | — | 1.6x | — | -34.83% | $57.95M |
| NTRBNutriBand Inc. | $4.46 | — | 9.0x | — | -145.72% | $54.22M |
| INKTMiNK Therapeutics, Inc. | $11.43 |
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Company description provided by Yahoo Finance.
| — |
| — |
| -18906.51% |
| ROE | -31.74% | -128.88% | -22.54% | -29.23% | -34.24% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $58.32M |
| XTNTXtant Medical Holdings, Inc. | $0.38 | — | 1.3x | — | -25.16% | $53.87M |
| SCYXScynexis Inc | $5.39 | — | 0.8x | — | -18.38% | $53.63M |